NCT07448623RecruitingPhase 1
A research study to look at the distribution and effects of coramitug on amyloid deposits in heart tissue using PET/CT imaging in people with ATTR amyloidosis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 6 Mar 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (estimated)
- First submitted
- 5 May 2025
- Start date
- 12 Feb 2026
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Amyloidosis
- EU CT number
- 2024-519372-22-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 14
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. Coordinator of this site? Confirm its status | Groningen | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.